欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (6): 717-720.

• 研究原著 • 上一篇    

罗格列酮与二甲双胍对2 型糖尿病患者血压的影响

李红辉, 刘恩波, 谢群, 丁殊节, 何涛1, 李家富1   

  1. 深圳市罗湖区人民医院内分泌科, 深圳518001, 广东; 1泸州医学院附属医院心内科, 泸州646000, 四川
  • 收稿日期:2005-01-19 修回日期:2005-04-21 出版日期:2005-06-26 发布日期:2020-11-12
  • 通讯作者: 李红辉, 女, 副主任医师, 副教授, 医学硕士, 主要从事内分泌临床研究。Tel:(0) 13798365308 E-mail: xwenq@sina.com

Influence of rosiglitazone and metformin on blood pressure in treatment of patients with type 2 diabetes mellitus

LI Hong-hui, LIU En-bo, XIE Qun, DING Su-jie, HE Tao1, LI Jia-fu1   

  1. Department of Endocrinology, Luohu People’s Hospital, Shenzhen 518001, Guangdong, China;1Department of Cardiology, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Guangxi, China
  • Received:2005-01-19 Revised:2005-04-21 Online:2005-06-26 Published:2020-11-12

摘要: 目的: 探讨罗格列酮和二甲双胍对2 型糖尿病患者血压的影响及其作用机制。方法: 58 例2 型糖尿病患者, 随机分成2 组, 分别口服罗格列酮(4 ~8 mg, qd) 和二甲双胍(250 ~ 500 mg, tid) 治疗, 在试验期间不使用其它对血压有影响的药物。观察治疗前后两组患者收缩压(SBP) 、舒张压(DBP) 、空腹血糖(FBG) 、餐后2 h 血糖(PBG) 、空腹血浆胰岛素(FINS) 、餐后2 h 血浆胰岛素(PINS) 水平, 共观察12周, 计算胰岛素敏感指数(ISI) 和胰岛素抵抗指数(IR) 。结果: 罗格列酮和二甲双胍治疗后收缩压和舒张压均有明显下降(P <0.05); 罗格列酮组SBP和DBP 降低幅度均大于二甲双胍组(P <0.05); 两组病例FBG 、PBG 、FINS 和PINS 均明显降低(P <0.05); 两组胰岛素敏感性的指标ISI 升高(P <0.05), 胰岛素抵抗的指标IR 下降(P <0.05), 罗格列酮组ISI 升高和IR 下降幅度大于二甲双胍组(P<0.05) 。结论: 罗格列酮和二甲双胍在改善胰岛素抵抗、提高胰岛素敏感指数的同时, 具有降低血压的作用, 罗格列酮的作用优于二甲双胍。

关键词: 罗格列酮, 二甲双胍, 2 型糖尿病, 血压, 胰岛素抵抗

Abstract: AIM: To investigate the influence of insulinsensitizer (Rosiglitazone) and metformin on blood pressure in treatment of patients with type 2 diabetes mellitus. METHODS: 58 patients with type 2 diabetes mellitus were randomly assigned to two groups.Patients orally received rosiglitazone 4-8 mg, qd, or metformin 250-500 mg, tid, for 12 weeks. The patients did not take any hypotensive drug during the investigation. BP, blood glucose and insulin were measured before and after treatment. The insulin resistance index and insulin sensitive index were calculated. RESULTS: SBP and DBP decreased after treatment by rosiglitazone and metformin (P <0.05). The decrease of blood pressure in rosiglitazone group were more than that in metformin group. FBG, PBG and FINS and PINS decreased after treatment (P < 0.05). ISI increased and IR decreased in the two groups (P <0.05). The extents of ISI and IR in rosiglitazone group were higher than that in metformin group. CONCLUSION: Rosiglitazone and metformin can effectively decrease IR and blood pressure, and the effect of rosiglitazone is better than that of metformin.

Key words: rosiglitazone, metformin, diabetes mellitus, blood pressure, insulinresistance

中图分类号: